Cargando…

Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome

BACKGROUND: Pathogenic mutations in FBN1, encoding the glycoprotein, fibrillin-1, cause Marfan syndrome (MFS) and related connective tissue disorders. In the present study, qualitative and quantitative effects of 16 mutations, identified in FBN1 in MFS patients with systematically described phenotyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tjeldhorn, Lena, Amundsen, Silja Svanstrøm, Barøy, Tuva, Rand-Hendriksen, Svend, Geiran, Odd, Frengen, Eirik, Paus, Benedicte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683784/
https://www.ncbi.nlm.nih.gov/pubmed/26684006
http://dx.doi.org/10.1186/s12881-015-0260-4
_version_ 1782406085819236352
author Tjeldhorn, Lena
Amundsen, Silja Svanstrøm
Barøy, Tuva
Rand-Hendriksen, Svend
Geiran, Odd
Frengen, Eirik
Paus, Benedicte
author_facet Tjeldhorn, Lena
Amundsen, Silja Svanstrøm
Barøy, Tuva
Rand-Hendriksen, Svend
Geiran, Odd
Frengen, Eirik
Paus, Benedicte
author_sort Tjeldhorn, Lena
collection PubMed
description BACKGROUND: Pathogenic mutations in FBN1, encoding the glycoprotein, fibrillin-1, cause Marfan syndrome (MFS) and related connective tissue disorders. In the present study, qualitative and quantitative effects of 16 mutations, identified in FBN1 in MFS patients with systematically described phenotypes, were investigated in vitro. METHODS: Qualitative analysis was performed with reverse transcription-PCR (RT-PCR) and gel electrophoresis, and quantitative analysis to determine the FBN1 mRNA levels in fibroblasts from the 16 patients with MFS was performed with real-time PCR. RESULTS: Qualitative analysis documented that the mutations c.4817-2delA and c.A4925G led to aberrant FBN1 mRNA splicing leading to in frame deletion of exon 39 and in exon 39, respectively. No difference in the mean FBN1 mRNA level was observed between the entire group of cases and controls, nor between the group of patients with missense mutations and controls. The mean expression levels associated with premature termination codon (PTC) and splice site mutations were significantly lower than the levels in patients with missense mutations. A high level of FBN1 mRNA in the patient with the missense mutation c.G2447T did not segregate with the mutation in three of his first degree relatives. No association was indicated between the FBN1 transcript level and specific phenotypic manifestations. CONCLUSIONS: Abnormal FBN1 transcripts were indicated in fibroblasts from patients with the splice site mutation c.4817-2delA and the missense mutation c.A4925G. While the mean FBN1 mRNA expression level in fibroblasts from patients with splice site and PTC mutations were lower than the mean level in patients with missense mutations and controls, inter-individual variability was high. The observation that high level of FBN1 mRNA in the patient with the missense mutation c.G2447T did not segregate with the mutation in the family suggests that variable expression of the normal FBN1 allele may contribute to explain the variability in FBN1 mRNA level. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12881-015-0260-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4683784
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46837842015-12-19 Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome Tjeldhorn, Lena Amundsen, Silja Svanstrøm Barøy, Tuva Rand-Hendriksen, Svend Geiran, Odd Frengen, Eirik Paus, Benedicte BMC Med Genet Research Article BACKGROUND: Pathogenic mutations in FBN1, encoding the glycoprotein, fibrillin-1, cause Marfan syndrome (MFS) and related connective tissue disorders. In the present study, qualitative and quantitative effects of 16 mutations, identified in FBN1 in MFS patients with systematically described phenotypes, were investigated in vitro. METHODS: Qualitative analysis was performed with reverse transcription-PCR (RT-PCR) and gel electrophoresis, and quantitative analysis to determine the FBN1 mRNA levels in fibroblasts from the 16 patients with MFS was performed with real-time PCR. RESULTS: Qualitative analysis documented that the mutations c.4817-2delA and c.A4925G led to aberrant FBN1 mRNA splicing leading to in frame deletion of exon 39 and in exon 39, respectively. No difference in the mean FBN1 mRNA level was observed between the entire group of cases and controls, nor between the group of patients with missense mutations and controls. The mean expression levels associated with premature termination codon (PTC) and splice site mutations were significantly lower than the levels in patients with missense mutations. A high level of FBN1 mRNA in the patient with the missense mutation c.G2447T did not segregate with the mutation in three of his first degree relatives. No association was indicated between the FBN1 transcript level and specific phenotypic manifestations. CONCLUSIONS: Abnormal FBN1 transcripts were indicated in fibroblasts from patients with the splice site mutation c.4817-2delA and the missense mutation c.A4925G. While the mean FBN1 mRNA expression level in fibroblasts from patients with splice site and PTC mutations were lower than the mean level in patients with missense mutations and controls, inter-individual variability was high. The observation that high level of FBN1 mRNA in the patient with the missense mutation c.G2447T did not segregate with the mutation in the family suggests that variable expression of the normal FBN1 allele may contribute to explain the variability in FBN1 mRNA level. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12881-015-0260-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-18 /pmc/articles/PMC4683784/ /pubmed/26684006 http://dx.doi.org/10.1186/s12881-015-0260-4 Text en © Tjeldhorn et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tjeldhorn, Lena
Amundsen, Silja Svanstrøm
Barøy, Tuva
Rand-Hendriksen, Svend
Geiran, Odd
Frengen, Eirik
Paus, Benedicte
Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome
title Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome
title_full Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome
title_fullStr Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome
title_full_unstemmed Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome
title_short Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome
title_sort qualitative and quantitative analysis of fbn1 mrna from 16 patients with marfan syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683784/
https://www.ncbi.nlm.nih.gov/pubmed/26684006
http://dx.doi.org/10.1186/s12881-015-0260-4
work_keys_str_mv AT tjeldhornlena qualitativeandquantitativeanalysisoffbn1mrnafrom16patientswithmarfansyndrome
AT amundsensiljasvanstrøm qualitativeandquantitativeanalysisoffbn1mrnafrom16patientswithmarfansyndrome
AT barøytuva qualitativeandquantitativeanalysisoffbn1mrnafrom16patientswithmarfansyndrome
AT randhendriksensvend qualitativeandquantitativeanalysisoffbn1mrnafrom16patientswithmarfansyndrome
AT geiranodd qualitativeandquantitativeanalysisoffbn1mrnafrom16patientswithmarfansyndrome
AT frengeneirik qualitativeandquantitativeanalysisoffbn1mrnafrom16patientswithmarfansyndrome
AT pausbenedicte qualitativeandquantitativeanalysisoffbn1mrnafrom16patientswithmarfansyndrome